Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.39 |
| ▸ | PDE4A | P27815 | 4/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383086 | 0.83 | PDE4B (0.38) | PDE4BPDE4APDE4CPDE4DCNR2 | |
| SCHEMBL4387542 | 0.81 | ESR1 (0.41) | PDE4BPDE4APDE4CPDE4DCNR2 | |
| SCHEMBL4389441 | 0.81 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4DCNR2 | |
| SCHEMBL4381978 | 0.81 | PDE4B (0.40) | PDE4BPDE4APDE4CPDE4DCNR2 | |
| SCHEMBL4386712 | 0.80 | FFAR1 (0.42) | PDE4BPDE4APDE4CPDE4DCNR2 | |
| SCHEMBL4386879 | 0.80 | CNR2 (0.42) | PDE4BPDE4APDE4CPDE4DCNR2 | |
| SCHEMBL4382744 | 0.79 | CNR2 (0.41) | PDE4BPDE4APDE4CPDE4DCNR2 | |
| SCHEMBL4381426 | 0.78 | CNR2 (0.40) | PDE4BPDE4APDE4CPDE4DCNR2 | |
| SCHEMBL4392291 | 0.78 | HK2 (0.42) | PDE4BPDE4APDE4CPDE4DCNR2 | |
| SCHEMBL2864985 | 0.77 | CNR2 (0.43) | PDE4BPDE4APDE4CPDE4DCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538241-B2 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070155813-A1 | Hsp90 family protein inhibitors | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1704856-A1 | HSP90 FAMILY PROTEIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155813-A1 | Hsp90 family protein inhibitors | HSP90AB1, HEATR1, HSP90AB2P | PDE4B 4266/4885PDE4A 4374/4885PDE4C 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.